Business Segments Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Equities
002603
CNE1000015S0
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.92 CNY | +0.07% |
|
-0.53% | -6.81% |
| 07-11 | Yiling Pharmaceutical Receives Regulatory Greenlight for Review of Banxia Baizhu Tianma Granules | MT |
| 07-08 | Yiling Pharmaceutical Gets Nod to Trial G201-Na Capsule | MT |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceutical Manufacturing | 8.78B | 10.12B | 12.53B | 10.32B | 6.51B | |||||
Total Assets | 11.49B | 12.9B | 16.34B | 16.98B | 13.32B | |||||
Interest Expense | -3.85M | -33.97M | -33.8M | -38.9M | -29.01M | |||||
Income Tax Expense | 208M | 212M | 424M | 340M | -66.01M | |||||
CAPEX | -1.14B | -674M | -214M | -311M | -290M | |||||
EBT | 1.42B | 1.55B | 2.78B | 1.68B | -800M | |||||
D&A | 264M | 358M | 447M | 545M | 611M | |||||
Operating Income | 1.44B | 1.57B | 2.83B | 1.78B | -689M | |||||
Net Income | 1.22B | 1.34B | 2.36B | 1.35B | -725M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
China | 8.48B | 9.76B | 12.07B | 10.08B | 6.22B | |||||
Foreign | 304M | 357M | 463M | 239M | 295M |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition